Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Cash from Operations (2017 - 2025)

Cue Biopharma's Cash from Operations history spans 9 years, with the latest figure at 9024000.0 for Q3 2025.

  • For Q3 2025, Cash from Operations fell 19.89% year-over-year to 9024000.0; the TTM value through Sep 2025 reached 29639000.0, up 22.53%, while the annual FY2024 figure was 36329000.0, 9.09% up from the prior year.
  • Cash from Operations for Q3 2025 was 9024000.0 at Cue Biopharma, down from 3415000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 3415000.0 in Q2 2025 and bottomed at 12848000.0 in Q2 2022.
  • The 5-year median for Cash from Operations is 9784000.0 (2024), against an average of 9344429.79.
  • The largest annual shift saw Cash from Operations tumbled 52.09% in 2021 before it skyrocketed 65.82% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 10645166.0 in 2021, then rose by 1.23% to 10514000.0 in 2022, then decreased by 4.22% to 10958000.0 in 2023, then rose by 17.61% to 9028000.0 in 2024, then grew by 0.04% to 9024000.0 in 2025.
  • Per Business Quant, the three most recent readings for CUE's Cash from Operations are 9024000.0 (Q3 2025), 3415000.0 (Q2 2025), and 8172000.0 (Q1 2025).